40,114 Shares of Regeneron Pharmaceuticals, Inc. $REGN Bought by Smith Group Asset Management LLC

Smith Group Asset Management LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, HoldingsChannel.com reports. The institutional investor purchased 40,114 shares of the biopharmaceutical company’s stock, valued at approximately $30,417,000. Regeneron Pharmaceuticals makes up about 2.0% of Smith Group Asset Management LLC’s portfolio, making the stock its 24th largest position.

Several other institutional investors have also recently added to or reduced their stakes in the stock. WestEnd Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 43.9% in the 3rd quarter. WestEnd Advisors LLC now owns 27,947 shares of the biopharmaceutical company’s stock valued at $21,194,000 after purchasing an additional 8,528 shares during the last quarter. SYM FINANCIAL Corp increased its holdings in shares of Regeneron Pharmaceuticals by 25.1% in the third quarter. SYM FINANCIAL Corp now owns 718 shares of the biopharmaceutical company’s stock valued at $544,000 after purchasing an additional 144 shares during the period. Oakworth Capital Inc. raised its stake in shares of Regeneron Pharmaceuticals by 25.0% during the third quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 14 shares during the last quarter. Ashton Thomas Securities LLC raised its stake in shares of Regeneron Pharmaceuticals by 24.6% during the third quarter. Ashton Thomas Securities LLC now owns 1,706 shares of the biopharmaceutical company’s stock worth $1,294,000 after purchasing an additional 337 shares during the last quarter. Finally, Penobscot Investment Management Company Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $243,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of REGN opened at $813.27 on Thursday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average is $791.72 and its two-hundred day moving average is $737.14. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $859.34. The firm has a market capitalization of $83.73 billion, a P/E ratio of 20.10, a PEG ratio of 1.36 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period last year, the company posted $12.81 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on REGN. The Goldman Sachs Group increased their price target on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Royal Bank Of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 8th. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Sanford C. Bernstein raised their target price on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a research note on Friday, August 14th. Finally, Wells Fargo & Company lifted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $847.90.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock worth $6,506,845 over the last quarter. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.